P1vital CNS Experimental Medicine Consortium
At a Glance
- Status: Completed Consortium
- Year Launched: 2008
- Initiating Organization: P1vital
- Initiator Type: Industry
- Disease focus:
- Location: Europe
Over a period of three years, P1vital funded a series of studies to establish the sensitivity of healthy volunteer central nervous system (CNS) experimental medicine models and to validate their ability to detect the efficacy of novel compounds.
The objective of the studies is to validate existing healthy volunteer models and to develop novel models in the areas of anxiety, cognitive disorders, depression, and schizophrenia.
The studies will be carried out by P1vital in collaboration with five internationally renowned academic clinical psychopharmacology groups in the United Kingdom based at the University of Bristol, Cardiff University, the Institute of Psychiatry, the University of Manchester, and the University of Oxford. The initial studies will validate new surrogate biomarkers for positive, negative, and cognitive deficits in schizophrenia. In depression, the consortium will validate an “at-risk” group (dysphoric volunteers) using a recently established emotional test battery as a surrogate population for depressed patients. In cognitive disorders, studies will focus on two recently developed virtual reality models and examine their utility for the early detection of cognitive deficits in mild cognitive impairment and schizophrenia. Studies will also investigate the potential efficacy of antidepressant drugs in treating anxiety disorders using an experimental model of anxiety.
Structure & Governance
Dr. Colin Dourish, CEO
Dr. Gerry Dawson, Chief Scientific Officer
Jonathan Kingslake, Chief Operating Officer
Dr. Nicole Srinivasan, Clinical Technical Director
Dr. John Hutchison, Medical Advisor
Dr. Belinda Pierce, Quality Assurance
David Priestley, Regulatory Affairs
P1vital’s advisory panel is comprised of internationally renowned psychopharmacologists and neuroscientists with expertise in anxiety, depression, schizophrenia, cognition, obesity, and addiction.
Impact / Accomplishment
P1vital CNS Experimental Medicine Consortium has produced many reviews and posters. They can be found at http://www.p1vital.com/public_documents/consortium_publications/publications.htmlP1
tel: +44(0)1865 522 030
fax: +44(0)1865 597 673
Oxfordshire, OX10 8BA
Sponsors & Partners
Organon – part of Schering-Plough and Wyeth